H M T El-Zimaity
Overview
Explore the profile of H M T El-Zimaity including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
255
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Graham D, Abudayyeh S, El-Zimaity H, Hoffman J, Reddy R, Opekun A
Aliment Pharmacol Ther
. 2006 Aug;
24(5):845-50.
PMID: 16918889
Background: The success rate of current anti-Helicobacter pylori triple therapies in now generally 80% or less. Sequential therapy has proved superior. Aim: To test a new sequential therapy for H....
2.
Cardenas V, Graham D, El-Zimaity H, Opekun A, Campos A, Chavez A, et al.
Aliment Pharmacol Ther
. 2006 Jan;
23(2):295-301.
PMID: 16393310
Background: Antibiotic resistance and duration of therapy influence the success of proton-pump inhibitor-containing Helicobacter pylori eradication therapy. Clarithromycin resistance is associated with treatment failure. Aim: To examine the success of...
3.
Yamaoka Y, Ojo O, Fujimoto S, Odenbreit S, Haas R, Gutierrez O, et al.
Gut
. 2005 Dec;
55(6):775-81.
PMID: 16322107
Background And Aims: A number of Helicobacter pylori outer membrane proteins (OMPs) undergo phase variations. This study examined the relation between OMP phase variations and clinical outcome. Methods: Expression of...
4.
Ricuarte O, Gutierrez O, Cardona H, Kim J, Graham D, El-Zimaity H
J Clin Pathol
. 2005 Oct;
58(11):1189-93.
PMID: 16254110
Background: Helicobacter pylori associated gastric cancer arises via a multistage process, with atrophic gastritis being the precursor lesion. Helicobacter pylori is typically acquired in childhood, yet little is known of...
5.
Kudo M, Gutierrez O, El-Zimaity H, Cardona H, Nurgalieva Z, Wu J, et al.
J Clin Pathol
. 2005 Mar;
58(3):259-62.
PMID: 15735156
Background: In the USA, atrophic gastritis and gastric cancer are rare, whereas gastro-oesophageal reflux disease (GERD) is common. Infection with Helicobacter pylori, especially a CagA positive strain, is unusual in...
6.
Graham D, Opekun A, Belson G, El-Zimaity H, Carlson M
Aliment Pharmacol Ther
. 2005 Feb;
21(2):165-8.
PMID: 15679766
Background: Current anti-Helicobacter pylori treatment regimens are costly and because of the increasing antibiotic resistance, are becoming ineffective. Aim: To evaluate a triple-layer tablet containing 100 mg bismuth subcitrate, 250...
7.
Graham D, Opekun A, Osato M, El-Zimaity H, Lee C, Yamaoka Y, et al.
Gut
. 2004 Aug;
53(9):1235-43.
PMID: 15306577
Background: A reliable challenge model is needed to evaluate Helicobacter pylori vaccine candidates. Methods: A cag pathogenicity island negative, OipA positive, multiple antibiotic susceptible strain of H pylori obtained from...
8.
Graham D, Belson G, Abudayyeh S, Osato M, Dore M, El-Zimaity H
Dig Liver Dis
. 2004 Jul;
36(6):384-7.
PMID: 15248377
Background: Quadruple therapy provided inadequate eradication rate when given twice-a-day at breakfast and evening meals. Aim: To test twice daily (mid-day and evening) quadruple therapy for Helicobacter pylori eradication. Methods:...
9.
Graham D, Hammoud F, El-Zimaity H, Kim J, Osato M, El-Serag H
Aliment Pharmacol Ther
. 2003 May;
17(10):1229-36.
PMID: 12755836
Aim: To compare H2-receptor antagonists and proton pump inhibitors as adjuvants to triple therapy for Helicobacter pylori eradication. Methods: H. pylori-infected patients with peptic ulcer were randomized to receive either...
10.
Graham D, Opekun A, Yamaoka Y, Osato M, El-Zimaity H
Aliment Pharmacol Ther
. 2003 Jan;
17(2):193-200.
PMID: 12534403
Background: Antisecretory therapy may exacerbate Helicobacter pylori corpus gastritis. The rate and mechanism(s) remain unknown. Aim: To investigate the early events in proton pump inhibitor therapy on antral and corpus...